Acadia Pharmaceuticals Inc. (ACAD)
ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality
Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID's patent protection now extends to 2030, supporting >10% Y/Y revenue growth and providing a stable revenue base. DAYBUE missed launch expectations but remains a durable rare-disease asset; ex-U.S. growth is likely to be modest.
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. ( ACAD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Albert Kildani Catherine Owen Adams - CEO & Director Thomas Garner - Executive VP & Chief Commercial Officer Elizabeth Thompson - Executive VP and Head of Research & Development Mark Schneyer - Executive VP & CFO Conference Call Participants Ritu Baral - TD Cowen, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Division So Youn Shim - UBS Investment Bank, Research Division Samuel Beck - Deutsche Bank AG, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Sean Laaman - Morgan Stanley, Research Division Tazeen Ahmad - BofA Securities, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Julian Hung - Stifel Nicolaus Canada Inc., Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Poorna Kannan - Needham & Company, LLC, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Good day, ladies and gentlemen, and thank you for standing by.
Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade
Acadia (ACAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
